ParenteralDosed ingredient Cosmetic cross-reference

Zinc Chloride

CAS 7646-85-7

Zinc Chloride (CAS 7646-85-7) is a Phase 4 pharmaceutical compound with 9 bioactivity targets and 174 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral

Adverse signals

174

SOURCE IUPHAR/BPS

PubMed IDs

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Zinc Chloride

CAS Number

7646-85-7

UNII

86Q357L16B

InChIKey

JIAARYAFYJHUJI-UHFFFAOYSA-L

ChEMBL ID

CHEMBL1200679

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

dosed ingredientparenteral

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)

Approved or marketed human pharmaceutical use is represented in the source phase field.

ChEMBL CHEMBL1200679 | Small molecule

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE EMBL-EBI ChEMBL 14 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	IC50	3307.0833333333335 nM	6	-
-	MIC	1706666.6666666667 nM	3	-
-	EC50	2020.8 nM	2	-
-	Ki	5644.75 nM	2	-
-	Kd	15700 nM	1	-
Sodium-dependent noradrenaline transporter Transporter	Ki	5.158	-	Homo sapiens
Carbonic anhydrase 2 Enzyme	IC50	5.936	-	Homo sapiens
Epidermal growth factor receptor Kinase	IC50	5.66	-	Homo sapiens
Tyrosine-protein kinase Fyn Kinase	IC50	5.726	-	Homo sapiens
Androgen receptor Transcription factor	Ki	5.363	-	Rattus norvegicus
Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform Enzyme	IC50	5.958	-	Homo sapiens
G-protein coupled receptor 39 GPCR	EC50	8.44	-	Homo sapiens
G protein-coupled receptor 39-1b GPCR	EC50	5.39	-	Rattus norvegicus
Ubiquitin-conjugating enzyme E2 T Enzyme	Kd	4.8	-	Homo sapiens

SOURCE DrugCentral 80 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PT	Drug AE	LLR	MedDRA
Sedation complication	229	598.046	10079741
Creatinine renal clearance decreased	229	552.178	10011372
Blood calcium decreased	240	456.71	10005395
Sedation	240	344.052	10039897
Orthostatic hypotension	238	334.621	10031127
Methaemoglobinaemia	114	329.75	10027496
Cognitive disorder	263	323.404	10057668
Balance disorder	276	264.129	10049848
Depressed level of consciousness	240	237.711	10012373
Mobility decreased	288	232.74	10048334
Constipation	423	195.897	10010774
Gastrointestinal toxicity	91	181.979	10059024
Pulmonary toxicity	92	157.485	10061924
COVID-19	256	137.199	10084268
Joint injury	107	120.762	10060820
Rhinocerebral mucormycosis	30	98.902	10076959
Macular degeneration	82	95.725	10025409
Neoplasm malignant	104	88.973	10028997
Pulmonary pain	40	82.656	10074693
Fall	418	72.727	10016173
Pain	599	68.553	10033371
Hepatotoxicity	100	66.847	10019851
Joint stiffness	87	60.377	10023230
Multiple drug therapy	30	58.59	10074950
Pemphigus	5	58.329	10034280
C-reactive protein abnormal	88	58.098	10068559
Copper deficiency	12	53.237	10010957
Aplastic anaemia	49	52.495	10002967
Synovitis	9	51.54	10042868
Sinusitis fungal	23	51.378	10058678
Illness	87	49.754	10080284
Hypotension	334	49.706	10021097
Systemic lupus erythematosus	14	47.512	10042945
Chronic sinusitis	43	47.413	10009137
Product dose omission issue	253	46.31	10084406
Acute kidney injury	92	44.516	10069339
Salpingo-oophorectomy unilateral	15	42.939	10039467
Radiation inflammation	15	40.82	10080826
Therapy non-responder	117	40.703	10051082
Amyloid arthropathy	13	40.222	10064554
Female genital tract fistula	28	38.792	10061149
Necrosis ischaemic	15	38.503	10028862
Nasal polyps	29	38.261	10028756
Hand deformity	10	37.979	10061194
Pericarditis	7	36.295	10034484
Maternal exposure during pregnancy	22	36.171	10071408
Musculoskeletal pain	114	35.694	10028391
Dermatitis atopic	34	34.097	10012438
Skin odour abnormal	18	33.697	10040904
Off label use	640	33.579	10053762

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE NLM RxNorm 3 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

Name	RxCUI	Type	Source
ZINC CHLORIDE	39937	SU	MTHSPL
Zinc Chloride	39937	SU	MTHSPL
zinc chloride	39937	IN	RXNORM

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Zinc Chloride used for in pharmaceutical contexts?

Zinc Chloride (CAS 7646-85-7) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Zinc Chloride?

Zinc Chloride has 174 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Sedation complication, Creatinine renal clearance decreased, Blood calcium decreased, Sedation, Orthostatic hypotension. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Zinc Chloride also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Zinc Chloride with EU status "restricted".

What clinical phase is Zinc Chloride in?

Zinc Chloride is rendered with ChEMBL max phase 4 (approved).

What bioactivity targets are documented for Zinc Chloride?

Zinc Chloride has 14 bioactivity rows in this page query. Rendered target entries include Sodium-dependent noradrenaline transporter, Carbonic anhydrase 2, Epidermal growth factor receptor, Tyrosine-protein kinase Fyn, Androgen receptor.